Hepatocellular Carcinoma (HCC) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer with liver cirrhosis, which develops following long periods of chronic liver disease. Cirrhosis is characterized by a decrease in hepatocyte proliferation, indicating exhaustion of the regenerative capacity of the liver, and results in an increase in fibrous tissue and destruction of liver cells, which may ultimately lead to the development of cancerous nodules. Half of all cases of HCC are associated with hepatitis B virus infection, with a further 25% associated with hepatitis C virus. Approximately, 70%–90% of patients with HCC have an established background of chronic liver disease and cirrhosis, including chronic infection with hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). Unresectable HCC is clinically a heterogeneous group of patients, which includes those with the intermediate stage (BCLC B) and advanced stage (BCLC C).

 

The competitive landscape of Hepatocellular Carcinoma (HCC) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Hepatocellular Carcinoma (HCC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hepatocellular Carcinoma (HCC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Hepatocellular Carcinoma (HCC)  – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Durvalumab Plus Tremelimumab            AstraZeneca     Phase 3

2          Fisogatinib in combination with CS1001  CStone Pharmaceuticals            Phase 2

3          AK104  Akeso Pharmaceuticals, Inc.      Phase 2

4          Milciclib maleate            Tiziana Life Sciences, PLC        Phase 2

5          Dalantercept plus sorafenib        Acceleron Pharma Inc.  Phase 2

6          CF102  Can-Fite BioPharma      Phase 2

7          SynOV1.1         Beijing Syngentech Co., Ltd.      Phase 1

8          Oral Pentamidine           Oncozyme Pharma Inc. Phase 1

9          YIV-906+Sorafenib        Yiviva Inc.         Phase 2

10        Cabozantinib tablets      Exelixis Phase 3

Continued